US5080898A
(en)
|
1982-05-12 |
1992-01-14 |
The University Hospital |
Enzymatically active toxin coupled to a cell-specific ligand
|
US5668255A
(en)
|
1984-06-07 |
1997-09-16 |
Seragen, Inc. |
Hybrid molecules having translocation region and cell-binding region
|
US6022950A
(en)
|
1984-06-07 |
2000-02-08 |
Seragen, Inc. |
Hybrid molecules having translocation region and cell-binding region
|
US5091178A
(en)
|
1986-02-21 |
1992-02-25 |
Oncogen |
Tumor therapy with biologically active anti-tumor antibodies
|
US7838216B1
(en)
|
1986-03-05 |
2010-11-23 |
The United States Of America, As Represented By The Department Of Health And Human Services |
Human gene related to but distinct from EGF receptor gene
|
JP3040121B2
(ja)
|
1988-01-12 |
2000-05-08 |
ジェネンテク,インコーポレイテッド |
増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
|
US5135736A
(en)
|
1988-08-15 |
1992-08-04 |
Neorx Corporation |
Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
|
DK0474727T3
(da)
|
1989-05-19 |
1998-01-12 |
Genentech Inc |
HER2 ekstracellulært domæne
|
AU657087B2
(en)
|
1989-12-22 |
1995-03-02 |
Seragen Incorporated |
Hybrid molecules having translocation region and cell-binding region
|
US5578482A
(en)
|
1990-05-25 |
1996-11-26 |
Georgetown University |
Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
|
US5635384A
(en)
|
1990-06-11 |
1997-06-03 |
Dowelanco |
Ribosome-inactivating proteins, inactive precursor forms thereof, a process for making and a method of using
|
US5834229A
(en)
|
1991-05-24 |
1998-11-10 |
Genentech, Inc. |
Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
|
IL101943A0
(en)
|
1991-05-24 |
1992-12-30 |
Genentech Inc |
Structure,production and use of heregulin
|
JP4124480B2
(ja)
|
1991-06-14 |
2008-07-23 |
ジェネンテック・インコーポレーテッド |
免疫グロブリン変異体
|
US6146850A
(en)
|
1991-11-04 |
2000-11-14 |
Xoma Corporation |
Proteins encoding gelonin sequences
|
US5621083A
(en)
|
1991-11-04 |
1997-04-15 |
Xoma Corporation |
Immunotoxins comprising ribosome-inactivating proteins
|
WO1993021319A1
(en)
|
1992-04-08 |
1993-10-28 |
Cetus Oncology Corporation |
HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
|
KR100269879B1
(ko)
|
1992-06-30 |
2000-10-16 |
폴 에이치. 피셔 |
항-이알비비-2모노클로날항체의 조합물 및 그 사용방법
|
FR2697695B1
(fr)
|
1992-11-04 |
1995-01-13 |
Cachan Ecole Normale Superieur |
Dispositif de conversion électromécanique produisant un mouvement en particulier linéaire.
|
US5869445A
(en)
|
1993-03-17 |
1999-02-09 |
University Of Washington |
Methods for eliciting or enhancing reactivity to HER-2/neu protein
|
JPH08510642A
(ja)
|
1993-05-12 |
1996-11-12 |
ゾマ コーポレイション |
ゲロニンおよび抗体から成る免疫毒素
|
JPH11506424A
(ja)
|
1995-03-24 |
1999-06-08 |
オフィディアン ファーマシューティカルズ インコーポレーテッド |
ベロ毒素産生大腸菌に対する治療
|
US5667786A
(en)
|
1995-06-07 |
1997-09-16 |
Novavax, Inc. |
Method for treating tumors with a toxin
|
EP2258726A1
(en)
|
1995-06-14 |
2010-12-08 |
The Regents of the University of California |
High affinity human antibodies to c-erbB-2
|
US5783186A
(en)
|
1995-12-05 |
1998-07-21 |
Amgen Inc. |
Antibody-induced apoptosis
|
US5858682A
(en)
|
1996-08-02 |
1999-01-12 |
Pharmingen |
E2A/pbx1 fusion protein specific monoclonal antibodies
|
WO1998007797A1
(fr)
|
1996-08-22 |
1998-02-26 |
Kaneka Corporation |
Composition durcissable pour revetement exterieur et articles ainsi recouverts
|
DE69732640T2
(de)
|
1996-09-09 |
2006-01-12 |
Zealand Pharma A/S |
Festphasen-peptidsynthese
|
AR010218A1
(es)
|
1996-09-10 |
2000-06-07 |
Military Henry M Jackson Foundation For The Advancement Of |
Una familia de proteinas bacterianas multi-unidad
|
US5770380A
(en)
|
1996-09-13 |
1998-06-23 |
University Of Pittsburgh |
Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
|
US6306393B1
(en)
|
1997-03-24 |
2001-10-23 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
FR2766193B1
(fr)
|
1997-07-18 |
2001-09-14 |
Inst Curie |
Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
|
CA2222993A1
(en)
|
1998-02-04 |
1999-08-04 |
The Ontario Cancer Institute |
A method for using a ribosome-inactivating protein complex as a structural template and a molecular search engine in the design, construction and screening of combinatorial protein libraries
|
JP2003524587A
(ja)
|
1998-06-05 |
2003-08-19 |
マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ |
多発性骨髄腫を処置するための、cd38に対する、遺伝子操作した抗体の使用
|
US7157418B1
(en)
|
1998-07-22 |
2007-01-02 |
Osprey Pharmaceuticals, Ltd. |
Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
|
JP4454152B2
(ja)
|
1998-07-22 |
2010-04-21 |
オスプレイ・ファーマシューティカルズ・ユーエスエイ・インコーポレイテッド |
二次的組織損傷ならびにその他の炎症症状および疾患を治療する方法および組成物
|
US6770456B1
(en)
|
1998-07-29 |
2004-08-03 |
Ludwig Institute For Cancer Research |
Endogenous retrovirus tumor associated nucleic acids and antigens
|
AU5963699A
(en)
|
1998-10-02 |
2000-04-26 |
Mcmaster University |
Spliced form of (erb)b-2/neu oncogene
|
US7625859B1
(en)
|
2000-02-16 |
2009-12-01 |
Oregon Health & Science University |
HER-2 binding antagonists
|
US7527787B2
(en)
|
2005-10-19 |
2009-05-05 |
Ibc Pharmaceuticals, Inc. |
Multivalent immunoglobulin-based bioactive assemblies
|
US7144991B2
(en)
|
1999-06-07 |
2006-12-05 |
Aletheon Pharmaceuticals, Inc. |
Streptavidin expressed gene fusions and methods of use thereof
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
ATE330967T1
(de)
|
1999-07-02 |
2006-07-15 |
Genentech Inc |
An her2 bindende peptidverbindungen
|
US6492498B1
(en)
|
1999-11-15 |
2002-12-10 |
Regents Of The University Of Minnesota |
Multimeric immunotoxins
|
US7267973B2
(en)
|
2000-03-22 |
2007-09-11 |
Sibtech, Inc. |
Nucleic acids encoding recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor
|
US20010031485A1
(en)
|
2000-03-22 |
2001-10-18 |
Sibtech, Inc. |
Recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor fragments
|
DK2857516T3
(en)
|
2000-04-11 |
2017-08-07 |
Genentech Inc |
Multivalent antibodies and uses thereof
|
US7306801B2
(en)
|
2000-05-15 |
2007-12-11 |
Health Research, Inc. |
Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
WO2003055439A2
(en)
|
2001-07-18 |
2003-07-10 |
The Regents Of The University Of California |
Her2/neu target antigen and use of same to stimulate an immune response
|
WO2003066854A1
(fr)
|
2002-02-04 |
2003-08-14 |
Yoshida, Hideo |
Agent anticancereux utilisant des variantes de verotoxines
|
US20040248151A1
(en)
|
2002-04-05 |
2004-12-09 |
Ventana Medical Systems, Inc. |
Method for predicting the response to HER2-directed therapy
|
SI2289942T1
(sl)
|
2002-04-10 |
2013-11-29 |
Genentech, Inc. |
Variante protitelesa proti HER2
|
US7449480B2
(en)
|
2002-05-14 |
2008-11-11 |
Baylor College Of Medicine |
Small molecule inhibitors of HER2 expression
|
AU2003237790A1
(en)
|
2002-05-14 |
2003-12-02 |
Baylor College Of Medicine |
Small molecule inhibitors of her2 expression
|
SI2289936T1
(sl)
|
2002-12-16 |
2017-10-30 |
Genentech, Inc. |
Imunoglobulinske variante in njihove uporabe
|
US7875586B2
(en)
|
2002-12-20 |
2011-01-25 |
The Johns Hopkins University |
Treatment of metastatic colon cancer with b-subunit of shiga toxin
|
US7282365B2
(en)
|
2003-01-03 |
2007-10-16 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Rhesus HER2/neu, nucleotides encoding same, and uses thereof
|
US7834258B2
(en)
|
2003-06-30 |
2010-11-16 |
Mu-Hyeon Choe |
Dimer of chimeric recombinant binding domain-functional group fusion formed via disulfide-bond-bridge and the processes for producing the same
|
EP1641818B1
(en)
|
2003-07-04 |
2008-12-03 |
Affibody AB |
Polypeptides having binding affinity for her2
|
EP1660010B1
(en)
|
2003-08-01 |
2013-07-24 |
A & G Pharmaceutical, Inc. |
Compositions and methods for restoring sensitivity to treatment with her2 antagonists
|
US8147832B2
(en)
|
2003-08-14 |
2012-04-03 |
Merck Patent Gmbh |
CD20-binding polypeptide compositions and methods
|
ATE468356T1
(de)
|
2003-11-25 |
2010-06-15 |
Us Gov Health & Human Serv |
Mutierte anti-cd22-antikörper und immunkonjugate
|
WO2005052129A2
(en)
|
2003-11-25 |
2005-06-09 |
Anjin Corporation |
Diptheria toxin variant
|
ATE467641T1
(de)
|
2004-03-26 |
2010-05-15 |
Molecular Templates Inc |
Bibliothek von toxin mutanten und deren verwendung
|
KR20180091967A
(ko)
|
2004-07-22 |
2018-08-16 |
제넨테크, 인크. |
Her2 항체 조성물
|
EP2535355B1
(en)
|
2005-03-23 |
2019-01-02 |
Genmab A/S |
Antibodies against CD38 for treatment of multiple myeloma
|
US7771955B2
(en)
|
2005-06-09 |
2010-08-10 |
University Of Maryland |
Affinity membrane for capture of a target biomolecule and formation thereof by site-directed immobilization of a capture biomolecule
|
MX2007015942A
(es)
|
2005-07-01 |
2008-03-07 |
Medarex Inc |
Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada.
|
FI20055417A0
(fi)
|
2005-07-20 |
2005-07-20 |
Glykos Finland Oy |
Syöpäpesifiset glykaanit ja niiden käyttö
|
BRPI0614183A2
(pt)
|
2005-07-25 |
2011-03-15 |
Trubion Pharmaceuticals Inc |
uso de dose única de moléculas de ligação especìficas para cd20
|
US20090156417A1
(en)
|
2005-09-26 |
2009-06-18 |
Jean Gariepy |
Library From Toxin Mutants, And Methods Of Using Same
|
EP1969165A4
(en)
|
2005-12-23 |
2010-05-19 |
Viventia Biotech Inc |
METHODS FOR GENERATING AND SCREENING HYBRID PROTEIN LIBRARIES, AND USES THEREOF
|
US8846058B2
(en)
|
2006-02-16 |
2014-09-30 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Shiga toxoid chimeric proteins
|
AU2007339753A1
(en)
|
2006-12-29 |
2008-07-10 |
Osprey Pharmaceuticals Usa, Inc. |
Methods of selecting and producing modified toxins, conjugates containing modified toxins and uses thereof
|
AU2008262391A1
(en)
|
2007-06-06 |
2008-12-18 |
Avi Biopharma, Inc. |
Soluble HER2 and HER3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease
|
US20090010966A1
(en)
|
2007-06-21 |
2009-01-08 |
Angelica Therapeutics, Inc. |
Modified diphtheria toxins
|
US7887801B2
(en)
|
2007-07-13 |
2011-02-15 |
Topotarget Germany Ag |
Optimized DNA and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins
|
EP2187971A2
(en)
|
2007-08-01 |
2010-05-26 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
A fold-back diabody diphtheria toxin immunotoxin and methods of use
|
DK2197903T3
(en)
|
2007-09-04 |
2015-01-05 |
Us Gov Health & Human Serv |
Deletions in Domain II from Pseudomonas exotoxin A that reduce non-specific TOXICITY
|
WO2009088403A2
(en)
|
2007-10-08 |
2009-07-16 |
Rutgers, The State University |
Nontoxic shiga-like toxin mutant compositions and methods
|
WO2009064815A1
(en)
|
2007-11-13 |
2009-05-22 |
The Scripps Research Institute |
Production of cytotoxic antibody-toxin fusion in eukaryotic algae
|
US20110189203A1
(en)
|
2007-11-27 |
2011-08-04 |
Ablynx N.V. |
Immunoglobulin constructs
|
JP5337815B2
(ja)
|
2007-12-17 |
2013-11-06 |
アンワイヤード プラネット エルエルシー |
多アンテナ受信機干渉除去方法及び装置
|
EP2072525A1
(en)
|
2007-12-21 |
2009-06-24 |
Affibody AB |
New polypeptides having affinity for HER2
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
EP2268297A4
(en)
|
2008-02-29 |
2011-11-16 |
Angelica Therapeutics Inc |
MODIFIED TOXINS
|
ES2342646B1
(es)
|
2008-06-02 |
2011-04-26 |
Institut De Recerca Hospital Universitari Vall Hebron |
Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
|
EP2318048B1
(en)
|
2008-07-21 |
2019-05-29 |
Immunomedics, Inc. |
Structural variants of antibodies for improved therapeutic characteristics
|
US20110280913A1
(en)
|
2008-07-31 |
2011-11-17 |
The Ohio State University |
Methods and Compositions for Delivering Therapeutic Agents in the Treatment of B-Cell Related Disorders
|
WO2010033229A2
(en)
|
2008-09-22 |
2010-03-25 |
Calmune Corporation |
Methods and vectors for display of molecules and displayed molecules and collections
|
WO2010085539A1
(en)
|
2009-01-23 |
2010-07-29 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Methods and compositions based on shiga toxin type 2 protein
|
WO2010122460A1
(en)
|
2009-04-20 |
2010-10-28 |
Pfizer Inc. |
Control of protein glycosylation and compositions and methods relating thereto
|
WO2011009624A1
(en)
|
2009-07-22 |
2011-01-27 |
Cenix Bioscience Gmbh |
Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
|
EP2464836A2
(en)
|
2009-08-14 |
2012-06-20 |
Unifrax I LLC |
Mounting mat for exhaust gas treatment device
|
EP2371864A1
(en)
|
2010-03-23 |
2011-10-05 |
Ganymed Pharmaceuticals AG |
Monoclonal antibodies for treatment of cancer
|
EP2558501B1
(en)
|
2010-04-15 |
2016-09-07 |
Alper Biotech, Llc |
Monoclonal antibodies against her2 antigens, and uses therefor
|
CA3051311A1
(en)
|
2010-05-27 |
2011-12-01 |
Genmab A/S |
Monoclonal antibodies against her2
|
GB201013989D0
(en)
|
2010-08-20 |
2010-10-06 |
Univ Southampton |
Biological materials and methods of using the same
|
PL219845B1
(pl)
|
2011-01-05 |
2015-07-31 |
Adamed Spółka Z Ograniczoną Odpowiedzialnością |
Przeciwnowotworowe białko fuzyjne
|
EP2667898A1
(en)
|
2011-01-26 |
2013-12-04 |
Cenix Bioscience GmbH |
Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
|
RU2636029C2
(ru)
|
2011-02-01 |
2017-11-17 |
Генмаб А/С |
Человеческие антитела и конъюгаты антитело-препарат против cd74
|
US8895006B2
(en)
|
2011-03-04 |
2014-11-25 |
Rutgers, The State University Of New Jersey |
Ricin ribosome binding protein compositions and methods of use thereof
|
KR20140036216A
(ko)
|
2011-05-06 |
2014-03-25 |
더 거번먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 레프리젠티드 바이 더 세크러터리 오브 더 디파트먼트 오브 헬쓰 앤드 휴먼 써비시즈 |
메소텔린을 표적화하는 재조합 면역독소
|
PL397167A1
(pl)
|
2011-11-28 |
2013-06-10 |
Adamed Spólka Z Ograniczona Odpowiedzialnoscia |
Przeciwnowotworowe bialko fuzyjne
|
JP2015509501A
(ja)
|
2012-02-23 |
2015-03-30 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
剤を細胞へ送達するための改変型微生物毒素受容体
|
KR101990341B1
(ko)
|
2013-03-12 |
2019-06-19 |
몰레큘러 템플레이츠, 인코퍼레이션. |
세포 내재화를 유도하기 위한 cd20-결합 면역독소 및 이의 사용 방법
|
GB2519786A
(en)
|
2013-10-30 |
2015-05-06 |
Sergej Michailovic Kiprijanov |
Multivalent antigen-binding protein molecules
|
US20160177284A1
(en)
|
2014-01-27 |
2016-06-23 |
Molecular Templates, Inc. |
Cell-targeted molecules comprising amino-terminus proximal or amino-terminal shiga toxin a subunit effector regions
|
IL287490B
(en)
|
2014-01-27 |
2022-08-01 |
Molecular Templates Inc |
Shiga toxin nonvaccine effector subunit-containing polypeptides for mammalian applications
|
US20210138076A2
(en)
|
2014-01-27 |
2021-05-13 |
Molecular Templates, Inc. |
Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
|
EP3102245B1
(en)
|
2014-02-05 |
2021-09-08 |
Molecular Templates, Inc. |
Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity
|
WO2015138435A1
(en)
|
2014-03-11 |
2015-09-17 |
Molecular Templates, Inc. |
Proteins comprising binding regions, shiga toxin a subunit effector regions, and carboxy-terminal, endoplasmic reticulum localization signal motifs
|
EP3872090A1
(en)
|
2014-03-11 |
2021-09-01 |
Molecular Templates, Inc. |
Proteins comprising amino-terminal proximal shiga toxin a subunit effector regions and cell-targeting immunoglobulin-type binding regions
|
US11142584B2
(en)
|
2014-03-11 |
2021-10-12 |
Molecular Templates, Inc. |
CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
|
EP3116858B1
(en)
|
2014-03-14 |
2020-11-11 |
RaQualia Pharma Inc. |
Azaspiro derivatives as trpm8 antagonists
|
CA2947048C
(en)
|
2014-06-11 |
2023-10-17 |
Molecular Templates, Inc. |
Protease-cleavage resistant, shiga toxin a subunit effector polypeptides and cell-targeted molecules comprising the same
|
KR20170018450A
(ko)
|
2014-06-18 |
2017-02-17 |
케모테라포이티쉐스 포르슝스인스티투트 게오르크-스파이어-하우스 |
세포 치료제로서의 car-발현 nk-92 세포
|
CN105713087B
(zh)
|
2014-11-12 |
2020-05-08 |
北京康乐卫士生物技术股份有限公司 |
人乳头瘤病毒58型单克隆抗体及其应用
|
KR20170110601A
(ko)
|
2015-02-05 |
2017-10-11 |
몰레큘러 템플레이츠, 인코퍼레이션. |
시가 독소 a 서브유닛 작동체 영역을 포함하는 다가 cd20 결합 분자 및 이들의 강화된 조성물
|
WO2016141303A2
(en)
|
2015-03-04 |
2016-09-09 |
Igm Biosciences, Inc. |
Cd20 binding molecules and uses thereof
|
IL292708B1
(en)
*
|
2015-05-30 |
2024-04-01 |
Molecular Templates Inc |
Vaccine-free Shiga toxin A subunit scaffolds and cell-targeting molecules containing them
|
CN107922493A
(zh)
|
2015-07-26 |
2018-04-17 |
分子模板公司 |
包含志贺毒素a亚基效应物和cd8+ t‑细胞表位的细胞靶向分子
|
EP3202783A1
(en)
|
2016-02-02 |
2017-08-09 |
Ecole Polytechnique Federale de Lausanne (EPFL) |
Engineered antigen presenting cells and uses thereof
|
KR102367074B1
(ko)
|
2016-03-29 |
2022-02-25 |
주식회사 에스티큐브 |
글리코실화된 pd-l1에 특이적인 이중 기능 항체 및 이의 사용 방법
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
AU2017348475B2
(en)
|
2016-10-30 |
2024-02-08 |
Shanghai Henlius Biotech, Inc. |
Anti-PD-L1 antibodies and variants
|
AU2017373962B2
(en)
|
2016-12-07 |
2022-03-31 |
Molecular Templates, Inc. |
Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
|
US11597914B2
(en)
|
2016-12-26 |
2023-03-07 |
Dankook University Cheonan Campus Industry Academic Cooperation Foundation |
IgG type monoclonal antibodies specifically binding to odontoblast surface
|
WO2018136553A1
(en)
|
2017-01-18 |
2018-07-26 |
Genentech, Inc. |
Idiotypic antibodies against anti-pd-l1 antibodies and uses thereof
|
US20200024312A1
(en)
|
2017-01-25 |
2020-01-23 |
Molecular Templates, Inc. |
Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes
|
US20200190138A1
(en)
|
2017-02-28 |
2020-06-18 |
Chugai Seiyaku Kabushiki Kaisha |
Protein purification with protein l
|
WO2018162749A1
(en)
|
2017-03-09 |
2018-09-13 |
Genmab A/S |
Antibodies against pd-l1
|
KR20190133198A
(ko)
|
2017-03-27 |
2019-12-02 |
셀진 코포레이션 |
면역원성의 감소를 위한 방법 및 조성물
|
JP7159151B2
(ja)
|
2017-09-25 |
2022-10-24 |
Jsr株式会社 |
イムノグロブリン結合タンパク質、及びそれを用いたアフィニティー担体
|
MX2020009743A
(es)
|
2018-03-19 |
2020-10-08 |
Abeome Corp |
Anticuerpos monoclonales neutralizantes de alta afinidad dirigidos contra el ligando de muerte programada 1 (pd-l1) y usos de estos.
|
IL268443B1
(en)
|
2018-04-17 |
2024-03-01 |
Molecular Templates Inc |
HER2-targeted molecules containing Shiga toxin subunit A scaffolds, without vaccination
|
WO2020081493A1
(en)
|
2018-10-16 |
2020-04-23 |
Molecular Templates, Inc. |
Pd-l1 binding proteins
|
WO2020154475A1
(en)
|
2019-01-23 |
2020-07-30 |
Molecular Templates, Inc. |
Proteins comprising modified immunoglobulin variable light chains
|